1 year return (CAGR)
-67.63%
Oncopeptides AB Exchange (ST, SEK)
ONCO.ST
1.63
+0.01 (+0.31%)
HealthcareBiotechnology
Loading...
3 year return (CAGR)
-30.46%
5 year return (CAGR)
-44.37%
10 year return (CAGR)
-
Computer Modeling Group 2027 Q1 - Turnarounds seldom turn?
Read MoreMarketcap
619.71M
Price/Sales
6.51
Ent value
659.18M
Price/Book
24.86
Div yield
0.00%
Growth years
-
Div growth
-
FCF payout
0.00%
Trailing P/E
-
PEG
-
Forward P/E
-
EPS growth
-41.60%
Stock information
What is a stock exchange? Operation, actors, examples
Read MoreStock chart
Loading...
Stock price data
| Open | 1.63 |
| Daily high | 1.66 |
| Daily low | 1.62 |
| Daily Volume | 726K |
| All-time high | 131.08 |
| 1y analyst estimate | 2.47 |
| Beta | -1.31 |
| EPS (TTM) | -0.56 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 19 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ONCO.ST | S&P500 | |
| Current price drop from All-time high | -98.76% | -2.63% |
| Highest price drop | -99.12% | -56.47% |
| Date of highest drop | 23 Jan 2025 | 9 Mar 2009 |
| Avg drop from high | -63.63% | -10.69% |
| Avg time to new high | 50 days | 12 days |
| Max time to new high | 2057 days | 1805 days |
News
Strong revenue growth and disciplined cost management position the company for positive cash flow in 2027, despite regional market challenges.
August 27, 2026
Oncopeptides AB (FRA:OND) reports impressive sales growth and strategic advancements, despite facing regional hurdles and regulatory delays.
May 13, 2026
Despite challenges in key markets, Oncopeptides AB (STU:OND) reports significant sales growth and outlines strategic initiatives to enhance its pipeline and market reach.
February 19, 2026
Oncopeptides AB (FRA:OND) reports a 174% increase in net sales and robust gross margins, while navigating operational and market expansion hurdles.
November 12, 2025